BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34837386)

  • 1. Dusp6 immunohistochemistry is associated with the response of atypical endometrial hyperplasia and early endometrial cancer to conservative treatment.
    Travaglino A; Raffone A; Gencarelli A; Micheli M; Franco L; Zullo F; Mollo A; Di Spiezio Sardo A; Bifulco G; Insabato L
    Int J Gynaecol Obstet; 2022 Sep; 158(3):742-747. PubMed ID: 34837386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
    Raffone A; Catena U; Travaglino A; Masciullo V; Spadola S; Della Corte L; Piermattei A; Insabato L; Zannoni GF; Scambia G; Zullo F; Bifulco G; Fanfani F; Di Spiezio Sardo A
    Gynecol Oncol; 2021 Jun; 161(3):795-801. PubMed ID: 33812697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Accuracy of Progesterone Receptor B in Young Women with Atypical Endometrial Hyperplasia and Early Endometrial Cancer Treated with Hysteroscopic Resection plus LNG-IUD Insertion.
    Raffone A; Travaglino A; Zullo FM; Gencarelli A; Micheli M; Miranda S; De Franciscis P; Insabato L; Di Spiezio Sardo A; Zullo F; Bifulco G
    J Minim Invasive Gynecol; 2021 Jun; 28(6):1244-1253. PubMed ID: 33122144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
    Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
    J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Predictive Factors of Response to Treatment in Patients Undergoing Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer.
    Raffone A; Travaglino A; Flacco ME; Iasevoli M; Mollo A; Guida M; Insabato L; Di Spiezio Sardo A; Carugno J; Zullo F
    J Adolesc Young Adult Oncol; 2021 Apr; 10(2):193-201. PubMed ID: 32799597
    [No Abstract]   [Full Text] [Related]  

  • 6. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
    Zhang H; Yan L; Bai Y; Li C; Guo Q; Wang C; Zhao X; Li M
    Gynecol Oncol; 2015 Mar; 136(3):549-53. PubMed ID: 25451692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
    Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
    Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment.
    Zhou S; Xu Z; Yang B; Guan J; Shan W; Shi Y; Chen X
    J Gynecol Oncol; 2021 Jul; 32(4):e57. PubMed ID: 34085795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA-seq and ATAC-seq analysis of CD163
    Wang L; Lv Q; Wu P; Luo S; Liu S; Chen X; Luo X
    Cancer Med; 2023 Mar; 12(5):5964-5978. PubMed ID: 36373483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
    Yang B; Xu Y; Zhu Q; Xie L; Shan W; Ning C; Xie B; Shi Y; Luo X; Zhang H; Chen X
    Gynecol Oncol; 2019 Apr; 153(1):55-62. PubMed ID: 30674421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conservative re-treatment of women with atypical endometrial hyperplasia and early endometrial carcinoma: We can hope, at least.
    Raffone A; Raimondo D; Rovero G; Travaglino A; Lopez G; Di Maio CM; Neola D; Raspollini A; Renzulli F; Filippelli A; Casadio P; Seracchioli R; Guida M
    Int J Gynaecol Obstet; 2024 May; 165(2):542-551. PubMed ID: 37772342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome.
    Wang L; Luo X; Wang Q; Lv Q; Wu P; Liu W; Chen X
    J Gynecol Oncol; 2021 Sep; 32(5):e70. PubMed ID: 34132069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hysteroscopic surgery combined with progesterone therapy on fertility and prognosis in patients with early endometrial cancer and atypical endometrial hyperplasia or endometrial intraepithelial neoplasia: a meta-analysis.
    Ye X; Li T
    Arch Gynecol Obstet; 2024 Jan; 309(1):259-268. PubMed ID: 37540307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
    Guan J; Chen XJ
    Front Endocrinol (Lausanne); 2022; 13():1041535. PubMed ID: 36387903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hysteroscopic inspection and total curettage are insufficient for discriminating endometrial cancer from atypical endometrial hyperplasia.
    Kurosawa H; Ito K; Nikura H; Takano T; Nagase S; Utsunomiya H; Otsuki T; Toyoshima M; Nagai T; Tanaka S; Watanabe M; Yaegashi N
    Tohoku J Exp Med; 2012 Dec; 228(4):365-70. PubMed ID: 23154663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer?
    Travaglino A; Raffone A; Saccone G; Mascolo M; Pignatiello S; Mollo A; De Placido G; Insabato L; Zullo F
    APMIS; 2019 Apr; 127(4):161-169. PubMed ID: 30803040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature.
    Rakha E; Wong SC; Soomro I; Chaudry Z; Sharma A; Deen S; Chan S; Abu J; Nunns D; Williamson K; McGregor A; Hammond R; Brown L
    Am J Surg Pathol; 2012 Nov; 36(11):1683-90. PubMed ID: 23073327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of complete regression in fertility-sparing patients with endometrial cancer and apical hyperplasia: the GLOBAL model in a large Chinese cohort.
    Li X; Wang Y; Wang J; Fan Y; Wang J
    J Transl Med; 2024 Feb; 22(1):127. PubMed ID: 38308352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.